1Rose PG,Mossbruger K,Fusco N,et al.Gemcitabine reverse cisplatin resistance:demonstration of activity in platinum-and multidrug-resistant ovarian and peritoneal carcinoma[J].Gynecol Oncol,2003,88 (1):17-21.
2Mini E,Nobili S,Caciagli B,et al.Cellular pharmacology of gemcitabine[J].Ann Oncol,2006,17 (5):7-12.
3Ward JL,Leung GP,Toan SV,et al.Functional analysis of site-directed glycosylation mutants of the human equiliabrative nucleoside transporter-2[J].Arch Biochem Biophys,2003,411 (1):19-26.
4Garcia-Manteiga J,Molina-Arcas M,Casado FJ,et al.Nucleoside transporter profiles in human pancreatic cancer cells:role of hCNT1 in 2'-2'-difluoro-deoxycytidine-induced cytotoxicity[J].Clin Cancer Res,2003,9 (13):5000-5008.
5Mackey JR,Jennings LL,Clarke ML,et al.Immunohistochemical variation of human equilibrative nucleoside transporter 1 in primary breast cancer[J].Clin Cancer Res,2002,8 (1):110-116.
6Spratlin J,Sangha R,Glubrecht D,et al.The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma[J].Clin Cancer Res,2004,10 (20):6956-6961.
7Karbownik M,Brzezianska E,Lewinski A,et al.Increased expression of mRNA specific for thymidine kinase,deoxycytidine kinase or thymidine phosphorylase in human papillary thyroid carcinoma[J].Cancer Lett,2005,225 (2):267-273.
8A1-Madhouna AS,van der Wiltc CL,Lovesc WJ,et al.Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluoro-deoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000[J].Biochem Pharmacol,2004,68 (4):601-609.
9Wilta CL,Kroepa JR,Lovesa WJR,et al.Expression of deoxycytidine kinase in leukemic cells compared with solid tumour cell lines,liver metastases and normal liver[J].Eur J Cancer,2003,39 (5):691-697.
10Sigmond J,Kroep JR,Loves W,et al.Quantitative real time PCR of deoxycytidine kinase mRNA by light cycler PCR in relation to enzyme activity and gemcitabine sensitivity[J].Cancer Lett,2004,213 (2):173-179.
